344 related articles for article (PubMed ID: 29903571)
1. Role of CXCL12 and CXCR4 in the pathogenesis of hematological malignancies.
Peled A; Klein S; Beider K; Burger JA; Abraham M
Cytokine; 2018 Sep; 109():11-16. PubMed ID: 29903571
[TBL] [Abstract][Full Text] [Related]
2. Role of CXCR4 in the pathogenesis of acute myeloid leukemia.
Peled A; Tavor S
Theranostics; 2013; 3(1):34-9. PubMed ID: 23382784
[TBL] [Abstract][Full Text] [Related]
3. Disturbed CXCR4/CXCL12 axis in paediatric precursor B-cell acute lymphoblastic leukaemia.
van den Berk LC; van der Veer A; Willemse ME; Theeuwes MJ; Luijendijk MW; Tong WH; van der Sluis IM; Pieters R; den Boer ML
Br J Haematol; 2014 Jul; 166(2):240-9. PubMed ID: 24697337
[TBL] [Abstract][Full Text] [Related]
4. [Level of SDF-1/CXCR4 in children with acute leukemia and its significance].
Wen Q; Chen RL; Cai KR; Lin YW
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2011 Apr; 19(2):324-6. PubMed ID: 21518481
[TBL] [Abstract][Full Text] [Related]
5. Dynamic chemotherapy-induced upregulation of CXCR4 expression: a mechanism of therapeutic resistance in pediatric AML.
Sison EA; McIntyre E; Magoon D; Brown P
Mol Cancer Res; 2013 Sep; 11(9):1004-16. PubMed ID: 23754844
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of CXCR4 by LY2624587, a Fully Humanized Anti-CXCR4 Antibody Induces Apoptosis of Hematologic Malignancies.
Peng SB; Zhang X; Paul D; Kays LM; Ye M; Vaillancourt P; Dowless M; Stancato LF; Stewart J; Uhlik MT; Long H; Chu S; Obungu VH
PLoS One; 2016; 11(3):e0150585. PubMed ID: 26954567
[TBL] [Abstract][Full Text] [Related]
7. [The expression and clinical significance of stromal cell-derived factor-1 and CXCR4 in acute leukemia and malignant lymphoma].
Zeng DF; Kong PY; Chen XH; Wei L; Chang C; Peng XG
Zhonghua Nei Ke Za Zhi; 2005 Jul; 44(7):522-4. PubMed ID: 16080846
[TBL] [Abstract][Full Text] [Related]
8. A CXCR4 antagonist leads to tumor suppression by activation of immune cells in a leukemia-induced microenvironment.
Han AR; Lee JY; Kim HJ; Min WS; Park G; Kim SH
Oncol Rep; 2015 Dec; 34(6):2880-8. PubMed ID: 26398122
[TBL] [Abstract][Full Text] [Related]
9. TGF-β-Neutralizing Antibody 1D11 Enhances Cytarabine-Induced Apoptosis in AML Cells in the Bone Marrow Microenvironment.
Tabe Y; Shi YX; Zeng Z; Jin L; Shikami M; Hatanaka Y; Miida T; Hsu FJ; Andreeff M; Konopleva M
PLoS One; 2013; 8(6):e62785. PubMed ID: 23826077
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of CXCR4 with the novel RCP168 peptide overcomes stroma-mediated chemoresistance in chronic and acute leukemias.
Zeng Z; Samudio IJ; Munsell M; An J; Huang Z; Estey E; Andreeff M; Konopleva M
Mol Cancer Ther; 2006 Dec; 5(12):3113-21. PubMed ID: 17172414
[TBL] [Abstract][Full Text] [Related]
11. Dissecting the role of the CXCL12/CXCR4 axis in acute myeloid leukaemia.
Ladikou EE; Chevassut T; Pepper CJ; Pepper AG
Br J Haematol; 2020 Jun; 189(5):815-825. PubMed ID: 32135579
[TBL] [Abstract][Full Text] [Related]
12. Role of CXCR4 in the progression and therapy of acute leukaemia.
Su L; Hu Z; Yang YG
Cell Prolif; 2021 Jul; 54(7):e13076. PubMed ID: 34050566
[TBL] [Abstract][Full Text] [Related]
13. Improving chemotherapeutic efficiency in acute myeloid leukemia treatments by chemically synthesized peptide interfering with CXCR4/CXCL12 axis.
Li X; Guo H; Duan H; Yang Y; Meng J; Liu J; Wang C; Xu H
Sci Rep; 2015 Nov; 5():16228. PubMed ID: 26538086
[TBL] [Abstract][Full Text] [Related]
14. BMS-936564/MDX-1338: a fully human anti-CXCR4 antibody induces apoptosis in vitro and shows antitumor activity in vivo in hematologic malignancies.
Kuhne MR; Mulvey T; Belanger B; Chen S; Pan C; Chong C; Cao F; Niekro W; Kempe T; Henning KA; Cohen LJ; Korman AJ; Cardarelli PM
Clin Cancer Res; 2013 Jan; 19(2):357-66. PubMed ID: 23213054
[TBL] [Abstract][Full Text] [Related]
15. [Significance of CXCL12/CXCR4 expression in T-lymphoblastic lymphoma/leukemia].
Yu ZZ; Xi YF; Li J; Bai WQ; Gao N; Bu P
Zhonghua Bing Li Xue Za Zhi; 2016 Dec; 45(12):838-843. PubMed ID: 28056298
[No Abstract] [Full Text] [Related]
16. CXCR4: a key receptor in the crosstalk between tumor cells and their microenvironment.
Burger JA; Kipps TJ
Blood; 2006 Mar; 107(5):1761-7. PubMed ID: 16269611
[TBL] [Abstract][Full Text] [Related]
17. A New Anti-CXCR4 Antibody That Blocks the CXCR4/SDF-1 Axis and Mobilizes Effector Cells.
Broussas M; Boute N; Akla B; Berger S; Beau-Larvor C; Champion T; Robert A; Beck A; Haeuw JF; Goetsch L; Bailly C; Dumontet C; Matthes T; Corvaia N; Klinguer-Hamour C
Mol Cancer Ther; 2016 Aug; 15(8):1890-9. PubMed ID: 27297868
[TBL] [Abstract][Full Text] [Related]
18. Functional response of leukaemic blasts to stromal cell-derived factor-1 correlates with preferential expression of the chemokine receptor CXCR4 in acute myelomonocytic and lymphoblastic leukaemia.
Möhle R; Schittenhelm M; Failenschmid C; Bautz F; Kratz-Albers K; Serve H; Brugger W; Kanz L
Br J Haematol; 2000 Sep; 110(3):563-72. PubMed ID: 10997965
[TBL] [Abstract][Full Text] [Related]
19. Drug design strategies focusing on the CXCR4/CXCR7/CXCL12 pathway in leukemia and lymphoma.
Barbieri F; Bajetto A; Thellung S; Würth R; Florio T
Expert Opin Drug Discov; 2016 Nov; 11(11):1093-1109. PubMed ID: 27598329
[TBL] [Abstract][Full Text] [Related]
20. Targeting the CXCL12/CXCR4 axis in acute myeloid leukemia: from bench to bedside.
Cho BS; Kim HJ; Konopleva M
Korean J Intern Med; 2017 Mar; 32(2):248-257. PubMed ID: 28219003
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
